• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention provides compounds of formula (2): and their pharmaceutically acceptable salts which are useful as histamine H1-antagonists. In formula (2) R' is halogen or nitro; R' is C1-4 alkyl: R3 is a C1-3 alkylene group; and R4 is 3-pyridyl; N-oxo-3-pyridyl; 6-methyl-3-pyridyl; N-oxo-6-methyl-3-pyridyl; 6-hydroxymethyl-3-pyridyl; 4,6-dimethyl-3-pyridyl; N-oxo-4.6-dimethyl-3-pyridyl; 6-hydroxymethyl-4-methyl-3-pyridyl; 5,6-dimethyl-3-pyridyl; N-oxo-5,6-dimethyl-3-pyridyl; 6-hydroxymethyl-5-methyl-3-pyridyl; 4-pyridyl or N-oxo-4-pyridyl.
    公开号:SU1232145A3
    申请号:SU823459055
    申请日:1982-06-25
    公开日:1986-05-15
    发明作者:Сидней Сач Джордж
    申请人:Смит Клайн Энд Фрэнч Лабораториз Лимитед (Фирма)；
    IPC主号:
    专利说明:


    The invention relates to a process for the preparation of new biologically active compounds, derivatives of pyrimidone or their pharmaceutically acceptable salts, which can be used in medicine.
    The purpose of the invention is to obtain new pyrimidone derivatives or their pharmaceutically acceptable salts with higher activity as histamine H antagonists.
    Example 1. A. 2- (2-Cyanoethyl) malnic acid diethyl ester (148.3 g) was borrowed from sodium hydride (15.3 g) in tetrahydrofuran at 20 ° C. 2-chloro-3- was added. methyl 5-nitropyridine (100g), and the internal temperature rises to 100 ° C over 14 hours (some amount of tetrahydrofuran is distilled off). The reaction mixture is partitioned between water and chloroform, the chloroform extract is taken up, treated with charcoal, filtered through a layer of silica and then evaporated to dryness. After crystallization of the residue from ethanol, A- (3-methyl-5- -nitropyrid-2-yl) -4,4-bis-carbethoxy-butyronitrile (99 g) is obtained. T, pl. 64 - 65.5 C.
    B. 4- (3-Methyl-5-nitropyrid-2-yl) -4,4-bis-carbethoxy-butyronitrile (99 g) is stirred in a mixture of ethanol (1200 ml) and a sodium hydroxide solution (1130 ml, mol During 16 hours, the pH was lowered to 2 by the addition of hydrochloric acid and the ethanol was distilled off. The product is extracted with chloroform to obtain an oil (57.1 g), which is extracted with dilute hydrochloric acid (554 ml, 1.5 g), again extracted with more dilute hydrochloric acid and the combined acidic extracts are treated with charcoal, filtered and then extracted with chloroform with obtaining 5-nitro-2 (3- -cyanopropyl) -3-methylpyridine
    (49.5 g) T. pl. 51.5-53 s.
    B. 5-Nitro-2- (3-cyanopropyl) -3- -methylpyridine (5.9 g) is hydrogenated with 3 ethanol (150 ml) with palladium on carbon (10%, 0.59 g) at 140 kPa for 2 5 "i. The filtered solution is concentrated to dryness, the residue is triturated with ether to give 5-amino-2- (3-cyanopropyl) -3

    50
    0
    five
    five
    145. -methylpyridine (4.70 g). M.p. 103 - 105 ° C.
    G. 5-amino-2- (3-cyanopropyl) -3- -methylpyridine (23.0 g) is reduced with lithium aluminum hydride (12.47 g) in a mixture with tetrahydrofuran (750 ml) and diethyl ether (750 ml) for 3 h, to obtain 5-amino-2- - (4-aminobutyl) -3-methylpyridine (20.6 g) as an amber oil.
    NMR (CDCl 3), distribution, 5 (mlnd), multiplicity: -CH CHjCH NH, 9 m, -3-CH, 2.22 s; CH2 (CH2), 2.6-2.8 m; 5-NH2, approximately 3.5 broad resonance} 4-pyridyl proton, 6.77 d; 6-pyridyl proton, 7.88 d.
    D. 5-amino-2- (4-aminobutyl) -3- -methylpyridine (5.11 g) in hydrobromic acid (48%, 47 ml) is reacted with copper bromide (4.98 g) and copper bronze (0.18 g).
    A solution of sodium nitrite (2.45 g) in water (16 ml) is added at 5-8 seconds for 45 minutes, the reaction mixture is stirred at 5-8 ° C for 1 more hour and then stirred at room temperature for 3.5 hours. the mixture is diluted with water. and hydrogen sulfide is passed in, while the pH is adjusted to 11 by the addition of sodium hydroxide solution. The precipitated copper salts are filtered off in parts during the reaction. The product is then extracted at pH 11 with chloroform to obtain 5-bromo-2 (4-aminobutyl) -3-methylpyridine (4.95 g). T. pl. 35-37 C.
    E. 5-Bromo-2- (4-aminobutyl) -3-methylpyridine (2.12 g) and 2-nitroamino-5- (6-methylpyrid-3-yl-metsh1) -4-pyrimidone (3.18 g) is heated under reflux in pyridine (12 ml) for 9.5 hours. Pyridine is removed by vacuum and the residue is evaporated with n-propanol (2 50 ml), triturated with chloroform, filtered and the solution is chromatographed on silica in the chloroform-methanol system (10: 1). The product is crystallized from ethanol-ether system to give (5-bromo-3-methylpyrid-2-yl) -butylamino-3-5- (6-methylpyrid-3-yl-methyl-4) pyrimidone (2.44 g). T. pl. 151-152 ° C.
    Calculated: With 57.01; H 5.46j N 15.83 ,, Br 18.06; C ,, H BrNgO
    3
    Found: C, 56.83; H 5.30; N 15.6 Vg 13.11.
    Example 2. In the interaction of 5-bromo-2- (4-aminobutyl) -3-methyl pyridine, the product of example 1 D (0.5 g with 2-methylthio-5- (pyrid-4-yl-met l) - - 4-pyrimidone (0.57 g) under conditions similar to those described in Example 1E, gives (5-bromo-3-methylpyrid-2-yl) -butylamino-3- (pyrid-4-ylmethyl) -pyrimidone (O, 15 g.) T. p. 176-177.5 C.
    Calculated: C 56.08, H 5.17; N 16.35, Br 18.65.
    S, „N ,,, ВГЫ50
    Found: C, 56.18; H 5.08; N 16.4 Bg 18.43.
    Example 3. After reacting 5-bromo-2- (4-aminobutyl) -3-methylpyridine, the product of example 1D (1.04 g), with 2-nitroamino-5- (L-oxo-6-methylpyrid -3-Sh1-methyl) -4-pyrimidone (1.42 g) under conditions similar to those described in Example 1E, give (5-bromo-3-methylpyrid--2-yl) -butylaminoJ-5- (N-oco-6-methyl pyrid-3-yl-methyl) -4-pyrimido n (0.48 g). T. pl. 193-194,5 S.
    Calculated: C 55.03; H 5.28; N 15.28; Вг 17.43.
    Cj, H24BrN502
    Found: C 54.67; H 5.41; N 15.09 Bg 17.60.
    Example 4. 2-f (4- (5-KpoM- -methylpyrid-2-yl) -butylamino} -5- - (N-OKco-6-methylpyrid-3-yl-methyl) -4-pyrimidone, product of example 3 (0.9 g), reacted with trifluoroacetic anhydride (1.65 g) in dichloromethane (6 ml) for 2 days, followed by removal of the solvent in vacuum, dissolving the residue in chloroform, washing the chloroform solution with 10% bicarbonate solution sodium i by concentrating the chloroform solution to dryness to give (5-bromo-3-methylpyrid-2-yl) -butshtamino-5- (6-hydroxymethyl-pyrid-3-yl-metsh1) -4-pyrimidone (0.42 g ). T, pl. 61-70 s, return to solid with at about 120 ° C, melted at 160-165 ° C.
    Calculated: C 52.50; H 5.50; N 14.56.
    C Hy ErttyO, 1.23 KgO Found: C 52.34; H 5.35, -N 14.49.
    32
    5 o
    15
    20 25
    thirty
    Q 0
    five
    1454
    Weight loss at 40-80 ° C, 4.6% (1.23).
    Example 5 A. After reacting 5-amino-2- (4-aminobutyl) -3-methylpyridine, the product of example 1 (1.5 g) with sodium nitrite, copper chloride, copper bronze and hydrochloric acid under the conditions analogous to that described in Example 1D, 5-chloro-2- (4-aminobutyl) -3-methylpyridine (1.0 g) is obtained. T. pl. P8-120 C.
    B. After reacting 5-chloro--2- (4-aminobutyl) -3-methylpyridine according to Example 5A (1.0 g) with 2-nitro-amino- 5- (6-meylpyrid-3-yl-methyl ) - -4-pyrimidone (1.23 g) under conditions similar to those described in Example 1E, give 2- f4- (5-chlorop-3- -methyl pyrid-2-yl) -butylamino-5- (6- -methylpyrid-3-yl-methyl) -4-pyrimidone (0.53 g). T. pl. UO-UI C.
    Calculated: C 63.39, - H 6.08; N 17.60; C1 8.91. Cj, H ClNyO
    Found: C, 63.18; H 6.22; N 17.42; C1 9.18.
    Example 6 A. 5-Nitro-3-methyl-2-cyanopropylpyridine (2 g) in tetrahydrofuran (20 ml) is reduced by diborane (0.045 mol) in tetrahydrofuran (45 ml) within 2 h 20 min . The reaction mixture is slowly added to ethanol (100 ml), stirred for 1 hour, acidified with hydrochloric acid (100 ml, molar), stirred for 20 minutes and concentrated to a low volume. The solution is washed with chloroform, alkalinized with sodium hydroxide to pH 12 and extracted with chloroform to obtain 3-methyl-5-nitro-2- (4-aminobutyl) pyridine as an oil (0.9 g).
    NMR (CDCl), distribution, S (mlnd), multiplicity: (CH) CH NH, 1.4 - 1.9 m; NH, 1.98 wide, s; 3-CH, 2.48, s; CH (CH.) 2CH., U, 2.7-3.1, m; 4-H pyridyl, 8.21 d; 6-H pyridyl, 9.19 d
    B. The product of Example 6A (0.85 g) is heated under reflux in pyridine (5 ml) with 2-nitroamino-5- (6-methylpyrid-3-yl-methyl) -4-pyrimidone (1.25 g ) in nitrogen 6 hours. Pyridine is removed in vacuo and the residue is chromatographed on silica in chloroform-methanol to give (5-nitro-3-methylpyrid-2-yl) -but 1-amino-5- (6-methylpyrid- H-nl-methyl) -A-pyrmndon (0.345 g). M.p. 141-142 p.
    Calculated: C61.75; H5.92; N 20.58.
    С ,, Н „ЫБО
    Found: C, 61.20; H 5.92; N 20.48.
    Example 7. A. 5-Amino-2- (4-α-aminobutyl) -3-methylpyridine (2.17 g) in 20% sulfuric acid (25 ml) at -5 ° C is reacted with sodium nitrate solution ( 1 g) in water (5 ml) for 20 minutes. After 15 minutes at -9 ° C, the reaction mixture was added to a mixture of potassium iodide (4 g) and copper iodide (0.5 g) in water (65 ml) with and then stirred at room temperature for 30 minutes. A saturated solution of sodium thiosulfate (10 ml) is added and the pH is adjusted to 12 with sodium hydroxide. After extraction with chloroform, the reaction mixture gives 5-iodo-3-methyl-2- (4-aminobutyl) -pyridine as a dark oil (2.45 g).
    NMR (CDClg), distribution, S (mlnd), multiplicity: (012) 7 CHzNH
    3-CH
    five.
    ,, Ш, 2.76 m;
    1.4-2.0 m; Sh-g, 1.69 s;
    2.28, s; CH2 (CH2) 2CH
    4-H pyridyl, 7.75 MJ 6-H pyridyl,
    8.57 m.
    B. The product of Example 7A (0.6 g) and 2-nitroamino-5- (6-methylpyrid-3-yl-methyl) -4-pyrimidone (0.6 g) is heated in pyridine (3 ml) for 5 hours. After removal of pyridine in vacuo, the residue is chromatographed in chloroform-methanol on silica with (5-iodo-3-methylpyrid-2-yl) -butylamine- (6-methylpyrid-3-yl-methyl) -4 pyrimidone. T. pl. 160-161.5 C.
    Example 8. A. A mixture of 5-amino-2- (4-amino-butyl) -3-methylpyridine (0.86 g) and fluoroboric acid (5 ml) in ethanol (30 ml) cooled to amyl nitrite (3 ml) for 15 minutes and then stirred for another 15 minutes, diluted with diethyl ether at 0 ° C to obtain 5-diazo-2- (4-aminobutyl) -3-3-methylpyridinefluoroborate (1.88 g). T. pl. 80-120 ° C (decomposition).
    This salt (1.78 g) was added portionwise to petroleum ether (75 ml), stirred at 95-100 to give an oil, which solidified upon cooling. Petroleum ether is decanted and the solid is partitioned between water and chloroform. The pH of the water portion was adjusted to 13 with sodium hydroxide and the product was extracted with chloroform to obtain 5-fluoro-2- (4-aminobutyl) -3-methylpyridine (0.69 g) as an amber oil. NMR (CDCl), distribution, 5
    (mlnd), multiplicity: NH, 1.39 wide with {CHj CH CH CHNNHj, 1.4 - 1.9 m; 3-CH, 2,3 s-, CH2 (CH.j) CH, NH2, 2.6-2.8 m, "4-H pyridyl; 7.14 d of d 6-H pyridyl, 8.19 d.
    B. The product of Example 8A (0.60 g) is heated under reflux in pyridine (3 ml) with 2-nitroamino-5- (6-methylpyrid-3-yl-methyl) -4-pyrimidone (0, 86 g) within 7 hours to obtain, after concentration, chromatography in the chloroform-methanol system and crystallization from acetonitrile, (5-fluoro-3-methyl-pyridyl--2-yl) butylamino-5- (b-methyl pyridine) -3-ylmethyl) -4-pyrimidone (1.04 g). T. pl. 131.5-133.5 ° C.
    Calculated: C, 66.16 j, H 6.35 {N 18.37.
    With 2 HjiijFNyO
    Found: C, 66.25; H 6.36; N 18.13.
    Example 9. The product of example 1 D (2.1 g) and 2-nitroamino-5- (5,6-dimethyl-N-oxo-pyrid-3-ip-methyl) -4-pyrimidone (2.51 g ) heated with
    reflux in pyridine (6 ml) for 13.5 hours. Pyridine is removed in vacuo, the last traces of pyridine are removed by distilling the azeotropic mixture with H-propanol.
    The residue is then dissolved in hot ethanol (50 ml) and any undissolved solid is filtered off. The filtrate is concentrated in a hot state to a volume of 20 ml.
    white forms during cooling
    crystals. They are recrystallized from ethanol and dimethylformamide to give (5-bromo-3-methyl-pyrid--2-yl) -butylamino-5- (5,6-dimethyl-pyridine-H-oxo-3-yl-methyl) -4-pyrimidone (2.5 g). M.p. 204-206 ° C.
    Calculated: C 55.81, H 5.60 -, N 15.00i Vg 17.23.
    C ,, H .BrNsO
    Found: C 55.93; H 5.54; N 14.82,
    Br 16.92.
    Example 10. The product of example 1 D (1.06 g) and 2-nitroamino-5- (K1-oxo-pyrid-D-yl-methyl) -D-pyrimidone (1.14 g) is heated under reflux in anisole ( 4 ml) for 7.5 hours. The anisole is removed in vacuo. The residue obtained is subjected to chromatography on silica in chloroform-methanol (4: 1). The product is crystallized from the acetone-itryl-water (9: 1) system to give - (5-bromo-3-methyl-pyridyl-2-yl) -butyl-amino-5- (H-oxo-pyrid-4-yl- methyl) -4-pyrimidone (0.40 g). T. pl. 110 -.
    .O
    Calculated: C 54.06; H 4.99; N 15.76; Br 17.98.
    B (1number: C 52.70, H 5.14; N 15.37, - Br 17.54.
    CioH, j, BrNyOj. 0.62
    Found: C, 52.68; H 4.92; N 15.45, Br 18.26.
    Example 11. A mixture of 5-bromo-2- - (4-aminobutyl) -3-methylpyridine. (0.68 g) and 2-nitroamino-5- (4,6-dimethyl-3-pyridylmethyl) -4- pyrimidone (0.83 g) in anisole (25 ml) is heated under reflux for 4 hours. Petroleum ether is added to precipitate the product, which is then subjected to silica gel column chromatography, and the chloroform is removed from the adsorbent. The product is crystallized from ethyl acetate to give (5-Crom-3-methyl-pyrid-2-nl) -butylamio-iZ-5- (4,6-dimethyl-3-pyridipimethyl) -4-pyrimidone (0.77 g). T. pl. 110-112 s.
    . Calculated: C 55.00; H 6.01; N 14.58; Br 16.63,
    CjjH eNjBrO. 1.27
    Found: C 54.87; H 5.93; N 14.38; Вг 16,33.
    Weight loss at 440-110 ° C 1.33.
    EXAMPLE 12 A mixture of 5-bromo-2- - (4-aminobutyl) -3-methylpyridine (0.68 g) and 2-nitrramino-5- (5,6-dimethyl-3-pyridylmethyl ) -4-pyrimidone (0.83 g) in anisole (25 ml) is heated under reflux for 4 hours. Excess petroleum ether is added to precipitate the product, which is then subjected to chromatography on a column of silica gel in CHCl. The product is crystallized in ether to give 2- 4- (5-bromo-3-methyl-pyrid-2-sh1) 10
    -butylamino-5- (5,6-dimethyl-3-pyridylmethyl) -4-pyrimidone (0.6 g). M.p. 126 - 128 ° C.
     Calculated: From 56,45 | H 5.87; N 14.96j Bg 17.07.
      0.6 HjO Found: C 56,44; H 5.68; N 14.82 {Br 16.96.
    Example 1H3 Trifluoroacetic anhydride (1.9 ml) was mixed with a suspension of the product of example 9 (1.6 g) in dry dichloromethane (10 ml) and the mixture was left to stand for two days. The solvent was removed in vacuo and the residue was dissolved in chloroform. The chloroform solution is washed with 10% sodium bicarbonate solution. After packing 2Q chloroform, a solid is obtained (1.7 g), which is crystallized from ethanol (10 mp) and added water (20 ml). Solid: recrystallized from system 25 acetonitrile - water (9: 1) to give (5-bromo-3-methylpyrid-2- - -yl) -butylamino-5- (5-methyl-6-ca: and - methylpyrid-3-yl-methyl) 4-pyrimidone (0.99 g). T. pl. 136-141 C.
    C.J, Hje BrNj-Oj
    Calculated: C 55.93, H 5.54; N 14.82; Br 16.92.
    Calculated: C, 51.97; H, 5.95; N 13.78; Vg 15.72.
    C zHjeBrNyO - 2.0 Found: C 51.82; H 5.89, N 13.83; Br 15.48.
    Example 14. A solution of 1,2-ethane-disulfonic acid (15.3 g) in methanol. (48 ml) is added to a solution of - (5-bromo-3-methyl) ids-2-yl) butyl-amino-5- (b-methyl-pyrid-3-yl-methide) -4-pyrimidone ( 20 g) in methanol (68 mp). The solid crystallizes upon cooling and is removed by filtration, washed with well methanol and dried to obtain the neutral salt of the ethanesulfonate, (5-bromo-3-methyl-pyrid-2-yl) -butyl-amine OJ-5- (6-methyl- pyrid-3-yl-methyl) -4-pyrimidone (31 g). T. pl. 182 - 185 C.
    Calculated: C 37.75} H 4.86f N 9.17; 12.60; Вг 10,46.
    Cj, .. obr. 1.5 2 Found: C 37.60 {H 4.78; N 9.10, 12.30; Вг 10,71.
    Example 15. Glacial acetic acid (0.52 ml) was added to a plant.
    five
    ENT-5-bromo-3-methyl-2- (aminobutyl) - - pyridine (1.0 g) in diethyl ether- (20 ml) with the formation of a white precipitate 5-bromo-3-methyl-2- (aminobu - thyl) -pyridine-acetate. The ether is removed under reduced pressure, 2-nitroamino (6-methylpyrid-3-yl-methyl) -4-pyrimidone (1.07 g) and pyridine are added and the reaction mixture is heated under reflux for 21 h.
    The crude mixture is evaporated in vacuo, the last traces of pyridine are removed by azeotropic distillation with i-propanol. Trituration of the residue in ethanol (10 ml) with ether and a few drops of water gives a solid (1.39 g). Recrystallization of a solid from a mixture of ethanol and ether a couple of times gives (5-bromo-3-methylpyrid-2-yl) butylamino-5- (6-methyl-pyrid-3-yl-methyl) -4-pyrimidone (1 , 0 g. Pl. 152-153 p.
    Example 16. A 5- (6-methyl-pyrid-3-yl) -methyl-3-thiouracil (2.33 g) and p-butyl bromide (1.37 g) were added to a solution of sodium hydroxide (0.8 g) in an aqueous solution of ethanol (58 ml). The mixture is heated to 70 ° C with stirring and stirred at this temperature for 1 hour. The mixture is then cooled to room temperature and left overnight. The reaction mixture is acidified with glacial acetic acid to pH 5. The solution is concentrated under reduced pressure, the solid thus formed is separated by filtration, washed with water and dried. A portion (g) of this solid was recrystallized from ethanol to give 2-p-butylthio-5- (6-methyl-pyrid-3-yl) -methyl-4-pyrimidone (0.8 g). T. pl. 171-172 seconds
    B. 2-11-Butylthio-5- (6-methyl-pyrid-3-yl) -methyl-4-pyrimidone (0.5 g) and 5-bromo-3- (4-aminobutyl) -3-methyl-pyridine (0.462 d) melted at for 8 hours. The melt is cooled, triturated with diethyl ether, after which the resulting solid is recrystallized from ethanol, to give 2- (5-bromo-3-methylpyrid-2-Sh1) -bu-
    Tylamino-5- (6-methylpyrid-3-ip-methyl) -4-pyrimidone (0.4 g). T. pl. 151 -.
    Example 17.A. 5- (6-Methyl-irid-3-yl) -methyl 3 -2-thiouracil (2.33 g). And benzylGromide (1.71 g) are added to a solution of atri oxide (0, 8 g) in ethanol (58 ml) and the mixture is heated to 50 ° C with stirring. After 10 minutes, the mixture was removed from the heated space and kept for an hour. The reaction mixture was acidified with glacial acetic acid to obtain a pH of 5 and concentrated under reduced pressure of about 40 ml. The solid thus precipitated is filtered off, washed with water and dried, thereby obtaining crude 2-benzylthio-5- (b-methylpyrid-3-yl) methyl-4-pyrone (2.1 g). T. pl. 235-237 C. Part of the substance obtained is used in the next operation without further purification.
    (c) 2-Beneyl-5- (6-methyl-pyrid-3-yl) -methyl-4-pyrimidone (0.5 g) and 2- (4-aminobutyl) -5-bromo-3-methyl-pyridine ( 0.343 g) is melted at 160 ° C for 7 hours. The melt is cooled, ground into powder, mixed with diethyl ether, and the solid thus obtained is recrystallized from ethanol-diethyl ether to give - (5-bromo-3 -methylpyrid-2-yl) -butyl-amino | -5- (6-methylpyrid-3-yl-methyl) -4-pyrimidone (0.33 g). T. pl. 151 - 154 ° C.
    Biological tests of the compounds obtained by the described method were carried out. Activity against the histamine H antagonist was demonstrated in vitro according to the results of the determination of the pAj ileum of the marine intestine
    pigs.
    The table contains comparative biological data for the proposed compounds and for the corresponding monosubstituted compounds. All compounds are divided into five groups. The first connection in each of the first
    the four groups is a compound prepared in accordance with the invention. The second compound in each group is the corresponding 5-monosubstituted compound. The last compound in the first group is the corresponding 3-methyl compound. The last group of compounds includes 3-monosubstituted halo and 3-monosubstituted methyl compounds, respectively.
    The higher the pА value, the higher the activity according to H. The selectivity of the compounds as H antagonists was demonstrated by the difference in the results obtained for the p I of the ileum and the pL of the atria. The greater the difference in results, the higher the selectivity. Antagonistic activity against H, in vitro is demonstrated by the narrowing of the bronchi. The lower the value obtained, the greater the activity.
    % j 2CH2CH2CHr, -NH% 0
    CH
    II
    III FCH, 8,616,68
    FH7,606,20
    IV
    Cl CH.
    Cl
    H
    In each of the groups, the 3,5-disamme1 compound possesses a higher level of H, activity in vitro, a higher level of selectivity for antagonistic activity towards H and H2, and finally a higher level of H — antagonistic activity in vivo.
    Offered compounds are more
    active than known. In addition, they have low toxicity.j when administered to guinea pigs 1T) .2500 mg / kg. .
    0
    CHfCVcH3
    0.03
    1.40
    0.19
    0.024
    2.1
    1,930, 068
    1,493,2
    8.585.57
    8,056,21
    3,010,03
    1,840.75
    权利要求:
    Claims (1)
    [1]
    A method of producing pyrimidone derivatives of the general formula n
    where Rj is a halogen;
    R 2 is alkyl with 1-4 carbon atoms;
    R, is alkylene with 1-3 carbon atoms;
    R 4 - 6-methyl-3-pyridyl, or their pharmaceutically acceptable salts, characterized in that the compound of the formula or its salt, where R ( , R * and Y e have the indicated meanings, are reacted with a compound of the general formula where R + has the specified value, Rj is alkylthio (C <-C 6 ) -benzylthio or nitroamino group, followed by isolation of the target product in free form or in the form of pharmaceutically acceptable salts.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1232145A3|1986-05-15|Method of producing pyrimidine derivatives or pharmaceutically acceptable salts thereof
    JP3042156B2|2000-05-15|Naphthalene derivative, its production method and its synthetic intermediate
    US4536580A|1985-08-20|4-Amino-5-bromo-2-methoxy-N-[8-|]-8-azabicyclo[3.2.1]-3-YL-benzamide or a pharmacologically acceptable acid addition salt thereof
    US4134983A|1979-01-16|3-amino-2-or-propoxyaryl substituted imidazoles
    HU180945B|1983-05-30|Process for preparing pyrimidones
    DE3522579C2|1995-10-12|Novel 1,4-dihydropyridine derivatives and salts thereof, processes for their preparation and pharmaceutical compositions containing the same
    EP0181136B1|1992-03-25|Oxindole antiinflammatory agents
    EP0221376B1|1990-06-20|N-substituted diphenyl piperidines
    EP0080154B1|1985-08-28|N-substituted 2-pyridyl indoles, process for their preparation, pharmaceutical compositions containing them, and their therapeutical use
    CA1287631C|1991-08-13|5-substituted-6-aminopyrimidine derivatives, composition and uses
    JPH07101861A|1995-04-18|Anti-asthmatic agent
    DE3027106C2|1988-11-10|
    SU1362402A3|1987-12-23|Method of obtaining derivatives of imidazole or their salts with acids
    US4950677A|1990-08-21|Benzimidazole derivative compounds and method of making
    EP0117345B1|1990-02-28|Aminopyrimidinones as histamine h2-antagonists
    DE60103752T2|2005-07-14|PROCESS FOR PREPARING PYRAZOLOPYRIDINE DERIVATIVES
    EP0039989A1|1981-11-18|Pyrimidone derivatives, processes for their preparation and pharmaceutical compositions containing them
    EP0115132B1|1987-03-04|Pyrimidone derivatives
    CA1166253A|1984-04-24|4-amino-6-|-3|-pyridazinones,preparation and cardiotonic use
    EP0107914A1|1984-05-09|Aminopyrimidinone derivatives useful as histamine H1-antagonists
    EP0512436A1|1992-11-11|Method for producing substituted pyridine derivatives
    US4329466A|1982-05-11|Certain nor-tropan-8-amine-3-aryl or heteroaryl derivatives
    Brañ et al.1994|Synthesis of 4-| oxazoles
    US4199580A|1980-04-22|3-Amino-2-or-propoxy-tetrahydronaphthyl or indanyl-substituted imidazoles and use
    US4567276A|1986-01-28|β-Adrenergic 2-[4-|phenyl]imidazoles
    同族专利:
    公开号 | 公开日
    IE821533L|1982-12-27|
    AU8535182A|1983-01-06|
    EP0068833A3|1983-03-30|
    FI822281L|1982-12-28|
    ZA824537B|1983-05-25|
    PL240628A1|1983-10-10|
    AT22891T|1986-11-15|
    CS480082A2|1985-06-13|
    ZA824580B|1983-05-25|
    JPS61233670A|1986-10-17|
    JO1185B1|1983-11-30|
    FI822281A0|1982-06-24|
    PL137627B1|1986-07-31|
    DK286982A|1982-12-28|
    US4535163A|1985-08-13|
    IE53348B1|1988-10-26|
    PL138524B1|1986-09-30|
    KR840000533A|1984-02-25|
    AT21900T|1986-09-15|
    EP0068833A2|1983-01-05|
    NO822120L|1982-12-28|
    JPS588079A|1983-01-18|
    EP0068834A2|1983-01-05|
    JPH0244812B2|1990-10-05|
    DE3273019D1|1986-10-09|
    JPS588080A|1983-01-18|
    DK287082A|1982-12-28|
    HU190396B|1986-08-28|
    DD202291A5|1983-09-07|
    YU138982A|1985-03-20|
    JPS6328424B2|1988-06-08|
    PT75074B|1986-02-26|
    EP0068834A3|1983-04-06|
    CS241036B2|1986-03-13|
    PH19680A|1986-06-13|
    IL66125A|1986-01-31|
    PT75074A|1982-07-01|
    ES8305755A1|1983-05-01|
    JPH0345073B2|1991-07-09|
    GR74925B|1984-07-12|
    EP0068834B1|1986-09-03|
    ZW13082A1|1982-09-29|
    PL237110A1|1983-06-20|
    PL137600B1|1986-07-31|
    NZ201077A|1985-09-13|
    AU8535282A|1983-01-06|
    KR880001475B1|1988-08-13|
    ES513469A0|1983-05-01|
    JPS61233616A|1986-10-17|
    DE3273782D1|1986-11-20|
    BG38163A3|1985-10-15|
    US4444772A|1984-04-24|
    EP0068833B1|1986-10-15|
    IL66125D0|1982-09-30|
    AU551066B2|1986-04-17|
    GR74926B|1984-07-12|
    US4486434A|1984-12-04|
    US4584381A|1986-04-22|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    IN146736B|1975-10-02|1979-08-25|Smith Kline French Lab|
    US4154834A|1975-12-29|1979-05-15|Smith Kline & French Laboratories Limited|Substituted isocytosines having histamine H2 -antagonist activity|
    MW5076A1|1975-12-29|1978-02-08|Smith Kline French Lab|Pharmacologicalle active compounds|
    US4216318A|1975-12-29|1980-08-05|Smith Kline & French Laboratories Limited|Heterocyclic alkyl 4-pyrimidones|
    US4227000A|1978-04-11|1980-10-07|Smith Kline & French Laboratories Limited|Intermediates in the process for making histamine antagonists|
    ZA792608B|1978-05-30|1980-06-25|Smith Kline French Lab|Nitro compounds|
    US4255428A|1979-03-24|1981-03-10|Smith Kline & French Laboratories Limited|5--4-pyrimidones|
    JPS55133379A|1979-04-05|1980-10-17|Smith Kline French Lab|Pyrimidone compound|
    EP0017680B1|1979-04-11|1982-04-21|Smith Kline & French Laboratories Limited|Pyrimidone derivatives, process for preparing them and pharmaceutical compositions containing them|
    JPS55145683A|1979-04-26|1980-11-13|Smith Kline French Lab|Pyrimidone derivative|IN151188B|1978-02-13|1983-03-05|Smith Kline French Lab|
    US4808589A|1982-02-20|1989-02-28|Smith Kline & French Laboratories Limited|Pyrimidone derivatives|
    GR78463B|1982-03-25|1984-09-27|Smith Kline French Lab|
    EP0093490B1|1982-03-25|1988-04-27|Smith Kline & French Laboratories Limited|Process for preparing 3,5-disubstituted 2-pyridylalkyl amines|
    PT77287B|1982-10-01|1986-02-04|Smith Kline French Lab|Compound|
    GB8319874D0|1983-07-23|1983-08-24|Smith Kline French Lab|Compounds|
    CA1286297C|1985-06-13|1991-07-16|George S. Sach|Pyridine derivatives|
    GB8601816D0|1986-01-25|1986-02-26|Smith Kline French Lab|Pyridine derivatives|
    GB8610867D0|1986-05-02|1986-06-11|Smith Kline French Lab|3-hydroxypyridines|
    JP2679977B2|1986-09-19|1997-11-19|株式会社日立製作所|Semiconductor integrated circuit|
    EP0364584A4|1988-04-27|1990-12-05|Kievsky Nauchno-Issledovatelsky Institut Farmakologii I Toxikologii|Antidote for organic phosphorus compound poisoning|
    US5216170A|1989-01-26|1993-06-01|Bayer Aktiengesellschaft| pyridines useful as intermediates|
    KR100498005B1|2002-07-26|2005-07-01|주식회사 소하드|Functional liquid fertilizer and preparation thereof|
    CA2510860C|2002-12-20|2012-10-09|Exxonmobil Chemical Patents Inc.|Polymerization process utilizing hydrofluorocarbons as diluents|
    US7443103B2|2005-06-24|2008-10-28|General Electric Company|High pressure lamp with lamp flicker suppression and lamp voltage control|
    BRPI0915541A2|2008-07-10|2016-01-26|Novartis Ag|aminobenzyl-substituted cyclic sulfones useful as bace inhibitors|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB8119906|1981-06-27|
    [返回顶部]